PK, Safety and Tolerability of Single and Multiple Doses of Oxfendazole Tablets

NCT ID: NCT04920292

Last Updated: 2022-12-20

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE1
• Total Enrollment: 30 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2022-04-21
• Study Completion Date: 2022-11-14

Brief Summary

The study evaluates the pharmacokinetics (PK), safety and tolerability of oxfendazole, after administration as a tablet formulation in healthy male and female participants.

Detailed Description

This is a randomized, placebo-controlled, double blinded, single center phase I bioavailability study with two Single Dose cohorts and one Multiple Doses cohort in a total of 30 healthy male and female healthy volunteers (10 per cohort).

Conditions

Filariasis

Keywords

Onchocerciasis; Parasitic Diseases; Neglected Disease; Phase I; Safety; Tolerability; Pharmacokinetics; Bioavailability; Volunteers

Study Design

• Allocation Method: RANDOMIZED
• Intervention Model: SEQUENTIAL
• Primary Study Purpose: TREATMENT
• Blinding Strategy: QUADRUPLE

Study Groups

Single Dose of 100mg Oxfendazole versus Placebo

8 participants will receive a single oral dose of 100mg of oxfendazole. 2 participants will receive a single oral dose of placebo.

Group Type: EXPERIMENTAL

Oxfendazole

Intervention Type: DRUG

Oxfendazole is a benzimidazole anthelminthic drug.

Placebo

Intervention Type: DRUG

The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Single Dose of 400mg Oxfendazole versus Placebo

8 participants will receive a single oral dose of 400mg of oxfendazole. 2 participants will receive a single oral dose of placebo.

Group Type: EXPERIMENTAL

Oxfendazole

Intervention Type: DRUG

Oxfendazole is a benzimidazole anthelminthic drug.

Placebo

Intervention Type: DRUG

The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Multiple Doses of 400mg Oxfendazole versus Placebo

8 participants will receive multiple oral doses of 400mg of oxfendazole on 5 consecutive days.

2 participants will receive multiple oral doses of placebo on 5 consecutive days.

Group Type: EXPERIMENTAL

Oxfendazole

Intervention Type: DRUG

Oxfendazole is a benzimidazole anthelminthic drug.

Placebo

Intervention Type: DRUG

The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Interventions

Oxfendazole

Oxfendazole is a benzimidazole anthelminthic drug.

Intervention Type: DRUG

Placebo

The placebo tablet is made using the same non-active ingredients and matches the investigational tablet.

Intervention Type: DRUG

Eligibility Criteria

Inclusion Criteria

• Healthy adult male and non-pregnant (confirmed by pregnancy test) and non-breastfeeding female participants (18 to 45 years of age at the time of consent).
• Willingness to give written consent to participate in the trial, after reading the participant information and consent form and after having had the opportunity to discuss the trial with the Investigator or any delegate.
• Ability to read and write and to understand the participant information sheet and the nature of the trial and any hazards from participating in it. Ability to communicate satisfactorily with the Investigator and to participate in, and comply with the requirements of, the entire trial.
• Women of childbearing potential (WOCBP) must agree to use a highly effective form of contraception in combination with a barrier method from at least 28 days prior to first dosage to 30 days after last dosage.
• Male participants must be willing to ensure the use of condoms from the first dosage to 90 days after last dosage.
• Normal body weight range (body mass index (BMI) between 18 and 29.9 kg/ m2)

Exclusion Criteria

• Participation in another clinical trial within 3 months prior to the study, or within 5-times the half-life of the drug tested in the previous clinical trial, whichever is longer. (Time calculated relative to the last dose in the previous clinical trial).
• Regular daily consumption of more than one liter of xanthine-containing beverages (e.g. chocolates, tea, coffee or cola drinks).
• Regular daily consumption of more than 5 cigarettes daily.
• Use of a prescription medicine during the 28 days before the first dose of trial medication or use of an over-the-counter medicine, during the 7 days before the first dose of trial medication.
• Use of dietary supplements or herbal remedies (such as St John's Wort) known to interfere with the CYP3A4 and/or P-gp metabolic pathway during the 28 days before the first dose of trial medication.
• Therapies which may impact on the interpretation of study results in the opinion of the Investigator.
• Medical, social condition, psychiatric disorder or occupational reasons that, in the judgment of the Investigator, is a contraindication to protocol participation, may impair the volunteer's ability to give informed consent or effectively participate in the study, may significantly increase the risk to the volunteer because of participation in the study or may impair interpretation of the study data.
• Blood pressure and heart rate in supine position at the screening examination outside one (or more) of the ranges 105-136 mm Hg systolic, 58-84 mm Hg diastolic; heart rate 56- 96 beats/min.
• Febrile illness within 1 week before the start of study treatment.
• History of relevant diseases of vital organs, of the central nervous system or other organs.
• Participants with a history of allergies, non-allergic drug reactions, adverse reaction to any drug, or multiple drug allergies.
• Participants with a hypersensitivity to the investigational drug, related benzimidazole compounds or the control agent and/ or to inactive constituents.
• Presence or history of drug or alcohol abuse in the last 10 years.
• Surgery (e.g. stomach bypass) or medical condition that might affect absorption of study drug taken orally.
• Clinically relevant abnormal medical history, concurrent medical condition, acute or chronic illness or history of chronic illness sufficient to invalidate the subject's participation in the trial or make it unnecessarily hazardous.
• Relevant pathological abnormalities in the ECG such as a second or third-degree atrioventricular (AV) block, prolongation of the QRS complex over 120 msec or of the QTcF-interval over 450 msec (corrected interval according to Fridericia's formula).
• Positive test for hepatitis B or C.
• Positive test for HIV.
• Positive pregnancy test (WOCBP).
• Positive stool or urine test for helminth infestation by Kato-Katz, urine filtration or Baermann test.
• Positive for malaria by thick blood smear.
• Positive test for (neuro-) cysticercosis.
• Positive test for echinococcosis.
• Positive test for onchocerciasis.
• Presence of abnormal physical findings, ECG, or laboratory values at the screening assessment that could interfere with the objectives of the trial or the safety of the subject.

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 45 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

Ifakara Health Institute

OTHER

Sponsor Role: collaborator

Drugs for Neglected Diseases

OTHER

Sponsor Role: collaborator

Swiss Tropical & Public Health Institute

OTHER

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Daniel Paris

Role: STUDY_DIRECTOR

Swiss TPH

Said Jongo

Role: PRINCIPAL_INVESTIGATOR

Ifakara Health Institute

Locations

Ifakara Health Institute

Bagamoyo, , Tanzania

Countries

Tanzania

Other Identifiers

P1773-20A

Identifier Type: -

Identifier Source: org_study_id